The DOI matches its Crossref record; 1,264 of the 1,264 references it cites were found in a registry or an index.
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Open accessAbstract
Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Herein, we summarize the discovery and development of tumor biomarkers, including the history of tumor biomarkers, the conventional and innovative technologies used for biomarker discovery and detection, the classification of tumor biomarkers based on tissue origins, and the application of tumor biomarkers in clinical cancer management. In particular, we highlight the recent advancements in biomarker-based anticancer-targeted therapies which are emerging as breakthroughs and promising cancer therapeutic strategies. We also discuss limitations and challenges that need to be addressed and provide insights and perspectives to turn challenges into opportunities in this field. Collectively, the discovery and application of multiple tumor biomarkers emphasized in this review may provide guidance on improved precision medicine, broaden horizons in future research directions, and expedite the clinical classification of cancer patients according to their molecular biomarkers rather than organs of origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 1,001–1,200 of 1,264
Selected In Situ Hybridization Methods: Principles and Application
Veselinyová, D., Mašlanková, J., Kalinová, K., Mičková, H., Mareková, M., & Rabajdová, M. (2021) · Molecules · doi:10.3390/molecules26133874 · Cited by 72
Ozkan, H., Kaya, M., & Cengiz, A. (2003) · PubMed · Cited by 71
Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
McCabe, K. E., Bacos, K., Lü, D., Delaney, J. R., Axelrod, J. L., Potter, M. D., Vamos, M., Wong, V., Cosford, N. D. P., Xiang, R., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.448 · Cited by 71
Li, J., Zhu, S., Tong, J., Hao, H., Yang, J., Liu, Z., & Wang, Y. (2015) · Neuroreport · doi:10.1097/wnr.0000000000000506 · Cited by 71
Mechanisms and significance of bifunctional NK4 in cancer treatment
Matsumoto, K., & Nakamura, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.131 · Cited by 70
Scagliotti, G., Kang, J. H., Smith, D. C., Rosenberg, R. K., Park, K., Kim, S.-W., Su, W., Boyd, T. E., Richards, D., Novello, S., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0368-1 · Cited by 70
Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer
Cheng, J., Li, Y., Wang, X., Dong, G., & Sheng, C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00929 · Cited by 70
Role of PDGF-A/B Ligands in Cardiac Repair After Myocardial Infarction
Kalra, K., Eberhard, J., Farbehi, N., Chong, J. J. H., & Xaymardan, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.669188 · Cited by 70
Park, H., Lee, S.-H., Lee, J., Moon, H., & Ro, S. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813764 · Cited by 70
Rizzi, F., Naponelli, V., Silva, A., Modernelli, A., Ramazzina, I., Bonacini, M., Tardito, S., Gatti, R., Uggeri, J., & Bettuzzi, S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt481 · Cited by 69
Markovina, S. T., Wang, S., Henke, L. E., Luke, C. J., Pak, S. C., DeWees, T. A., Pfeifer, J. D., Schwarz, J. K., Liu, W., Chen, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.390 · Cited by 69
N-cadherin antagonists as oncology therapeutics
Blaschuk, O. W. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0039 · Cited by 68
Matsuki, M., Adachi, Y., Ozawa, Y., Kimura, T., Hoshi, T., Okamoto, K., Tohyama, O., Mitsuhashi, K. O., Yamaguchi, A., Matsui, J., et al. (2017) · Cancer Science · doi:10.1111/cas.13169 · Cited by 68
Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34
Robke, L., Laraia, L., Corrales, M. A. C., Konstantinidis, G., Muroi, M., Richters, A., Winzker, M., Engbring, T., Tomassi, S., Watanabe, N., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201703738 · Cited by 68
Salah, S. H., Lewin, J. H., Amir, E., & Razak, A. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.05.007 · Cited by 68
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
Randon, G., Fucà, G., Rossini, D., Raimondi, A., Pagani, F., Perrone, F., Tamborini, E., Busico, A., Peverelli, G., Morano, F., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39525-3 · Cited by 68
Thies, K., Hammer, A. M., Hildreth, B. E., Steck, S., Spehar, J. M., Kladney, R. D., Geisler, J. A., Das, M., Russell, L., Bey, J. F., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3731 · Cited by 68
Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
Junttila, M. R., Devasthali, V., Cheng, J. H., Castillo, J., Metcalfe, C., Clermont, A. C., Otter, D. D., Chan, E., Bou-Reslan, H., Cao, T. C., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0030 · Cited by 67
miR-26b inhibits autophagy by targeting ULK2 in prostate cancer cells
Clotaire, D. Z. J., Zhang, B., Wei, N., Gao, R., Zhao, F., Wang, Y., Lei, M., & Huang, W. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.093 · Cited by 67
Fearon, E. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00087-4 · Cited by 66
Small molecule inhibition of fibroblast growth factor receptors in cancer
Liang, G., Chen, G., Wei, X., Zhao, Y., & Li, X. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.05.002 · Cited by 66
Self-citationReifenberger, G., Szym�s, J., & Wechsler, W. (1987) · Acta Neuropathologica · doi:10.1007/bf00692841 · Cited by 66
Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor
Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., Burgess, K., Qiu, M., Engstrom, L. D., Yamazaki, S., Parker, M., Timofeevski, S. L., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0839 · Cited by 66
Fujiwara, Y., Tamura, K., Kondo, S., Tanabe, Y., Iwasa, S., Shimomura, A., Kitano, S., Ogasawara, K., Turner, P. K., Mori, J., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3085-8 · Cited by 66
Clinical Applications of Autophagy Proteins in Cancer: From Potential Targets to Biomarkers
Bortnik, S. B., & Gorski, S. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071496 · Cited by 66
A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications
Wang, M., & Attardi, L. D. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-025840 · Cited by 66
Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021
Zhang, C., Sun, C., Zhao, Y., Wang, Q., Guo, J., Ye, B., & Yu, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911389 · Cited by 66
Self-citationSaito, T., Nishimura, M., Yamasaki, H., & Kudo, R. (2003) · Cancer · doi:10.1002/cncr.11157 · Cited by 65
??-Fetoprotein and ??-Human Chorionic Gonadotropin: Their Clinical Significance as Tumour Markers
Gregory, J. J., & Finlay, J. L. (1999) · Drugs · doi:10.2165/00003495-199957040-00001 · Cited by 65
Relevance of necroptosis in cancer
Lalaoui, N., & Brumatti, G. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.120 · Cited by 65
Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer
Camorani, S., Hill, B. S., Collina, F., Gargiulo, S., Napolitano, M., Cantile, M., Bonito, M. D., Botti, G., Fedele, M., Zannetti, A., et al. (2018) · Theranostics · doi:10.7150/thno.27798 · Cited by 65
Low NLRP3 expression predicts a better prognosis of colorectal cancer
Shi, F., Wei, B., Lan, T., Xiao, Y., Quan, X., Chen, J., Zhao, C., & Gao, J. (2021) · Bioscience Reports · doi:10.1042/bsr20210280 · Cited by 65
Deng, J., Paulus, A., Fang, D. D., Manna, A., Wang, G., Wang, H., Zhu, S., Chen, J., Min, P., Yin, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4037 · Cited by 65
Booth, J. C., Hannington, G., Bakir, T. M. F., et al. (1982) · Journal of Clinical Pathology · doi:10.1136/jcp.35.12.1345 · Cited by 64
Crosstalk between autophagy and microbiota in cancer progression
Wang, Y., Du, J., Wu, X., Abdelrehem, A., Ren, Y., Liu, C., Zhou, X., & Wang, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01461-0 · Cited by 64
Gautam, J., Banskota, S., Lee, H., Lee, Y., Jeon, Y. H., Kim, J., & Jeong, B. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0135-9 · Cited by 63
Lin, L.-H., Lin, J.-S., Yang, C.-C., Cheng, H.-W., Chang, K., & Liu, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072360 · Cited by 63
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105579 · Cited by 63
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
Nakamura, I. T., Kohsaka, S., Ikegami, M., Ikeuchi, H., Ueno, T., Li, K., Beyett, T. S., Koyama, T., Shimizu, T., Yamamoto, N., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00204-0 · Cited by 63
Faiella, A., Riccardi, F., Cartenì, G., Chiurazzi, M., & Onofrio, L. (2022) · Journal of Oncology · doi:10.1155/2022/5179182 · Cited by 63
Shen, H., Lundy, J., Strickland, A. H., Harris, M., Swan, M. P., Desmond, C., Jenkins, B. J., & Croagh, D. G. (2022) · Cells · doi:10.3390/cells11193175 · Cited by 63
The effects of mutant Ras proteins on the cell signalome
Takács, T., Kudlik, G., Kurilla, A., Szeder, B., Buday, L., & Vas, V. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09912-8 · Cited by 62
Rizvi, N. A., Humphrey, J. S., Ness, E. A., Johnson, M. D., Gupta, E., Williams, K., Daly, D. J., Sonnichsen, D. S., Conway, D. A., Marshall, J. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1183-02 · Cited by 62
Syed, S. K., Takimoto, C. H. M., Hidalgo, M. M., Rizzo, J. D., Kuhn, J. G., Hammond, L. A., Schwartz, G. H., Tolcher, A. W., Patnaik, A., Eckhardt, S. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0804 · Cited by 62
Razaghi, A., Heimann, K., Schaeffer, P. M., & Gibson, S. B. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1440-4 · Cited by 62
A new quinoline-based chemical probe inhibits the autophagy-related cysteine protease ATG4B
Bosc, D., Vezenkov, L., Bortnik, S. B., An, J., Xu, J., Choutka, C., Hannigan, A. M., Kovacic, S., Loo, S., Clark, P. G. K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29900-x · Cited by 62
Self-citationChronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer
Akinwunmi, B. O., Babić, A., Vitonis, A. F., Cramer, D. W., Titus, L. J., Tworoger, S. S., & Terry, K. L. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0203 · Cited by 62
Huang, X., Xiao, F., Li, Y., Qian, W., Ding, W., & Ye, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0976-z · Cited by 62
Deng, H., Huang, L., Liao, Z., Liu, M., Li, Q., & Xu, R. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02742-0 · Cited by 62
FDA Approves First KRAS Inhibitor: Sotorasib
(2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2021-0362 · Cited by 62
Zimmermann, A., Zenke, F. T., Chiu, L.-Y., Dahmen, H., Pehl, U., Fuchß, T., Grombacher, T., Blume, B., Vassilev, L. T., & Blaukat, A. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0934 · Cited by 62
Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping
Luo, G., Guo, M., Jin, K., Liu, Z., Liu, C., Cheng, H., Yu, L., Long, J., Liu, L., Xu, J., et al. (2016) · Pancreatology · doi:10.1016/j.pan.2016.09.013 · Cited by 61
Self-citationMMP1 and MMP9 are potential prognostic biomarkers and targets for uveal melanoma
Wang, T., Zhang, Y., Bai, J., Xue, Y., & Peng, Q. (2021) · BMC Cancer · doi:10.1186/s12885-021-08788-3 · Cited by 61
Self-citationPARP inhibitors in gastric cancer: beacon of hope
Wang, Y., Zheng, K., Huang, Y., Xiong, H., Su, J., Chen, R., & Zou, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02005-6 · Cited by 61
Biomarkers in Prostate Cancer Epidemiology
Verma, M. K., Patel, P., & Verma, M. (2011) · Cancers · doi:10.3390/cancers3043773 · Cited by 60
Wójcik, E., & Kulpa, J. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s149516 · Cited by 60
Patnaik, A., Gordon, M. S., Tsai, F. Y.-C., Papadopoulos, K. P., Rasco, D. W., Beeram, S., Fu, S., Jankú, F., Hynes, S. M., Gundala, S. R., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3623-7 · Cited by 60
Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo
Ogasawara, S., Mihara, Y., Kondo, R., Kusano, H., Akiba, J., & Yano, H. (2019) · Anticancer Research · doi:10.21873/anticanres.13802 · Cited by 60
Bresalier, R. S., Grady, W. M., Markowitz, S. D., Nielsen, H. J., Batra, S. K., & Lampe, P. D. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0234 · Cited by 60
Liquid biopsy in pancreatic cancer – Current perspective and future outlook
Zhao, Y., Tang, J., Jiang, K., Liu, S.-Y., Aicher, A., & Heeschen, C. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188868 · Cited by 60
Self-citationIwadate, R., Inoue, J., Tsuda, H., Takano, M., Furuya, K., Hirasawa, A., Aoki, D., & Inazawa, J. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.05.008 · Cited by 59
Hu, P., Liu, Q., Deng, G., Zhang, J., Liang, N., Xie, J., & Zhang, J. (2017) · Scientific Reports · doi:10.1038/srep42913 · Cited by 59
Emerging clinical relevance of microbiome in cancer: promising biomarkers and therapeutic targets
Dai, J.-H., Tan, X.-R., Qiao, H., & Liu, N. (2023) · Protein & Cell · doi:10.1093/procel/pwad052 · Cited by 59
Kosaka, T., Kikuchi, E., Mikami, S., Miyajima, A., Shirotake, S., Ishida, M., Okada, Y., & Oya, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0230 · Cited by 58
Mizuno, S., & Nakamura, T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14010888 · Cited by 58
Matrix metalloproteinase 9 (MMP-9) in osteosarcoma: Review and meta-analysis
Wang, J., Shi, Q., Yuan, T., Song, Q.-L., Zhang, Y., Wei, Q., Zhou, L., Luo, J., Zuo, G., Tang, M., et al. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.03.023 · Cited by 58
Self-citationThe role of HGF/c-MET signaling pathway in lymphoma
Lam, B., Dai, L., & Qin, Z. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0366-y · Cited by 58
BH3-Only Proteins and Their Effects on Cancer
Vo, T.-T. T., & Letai, A. G. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6706-0_3 · Cited by 57
Ravandi, F., Gojo, I., Patnaik, M. M., Minden, M. D., Kantarjian, H., Johnson-Levonas, A. O., Fancourt, C., Lam, R., Jones, M. B., Knox, C. D., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.07.004 · Cited by 57
Zhou, Z., Zhou, G., Zhou, C., Fan, Z., Cui, R., Li, Y., Li, R., Gu, Y., Li, H., Ge, Z., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00075 · Cited by 57
Falcón, B. L., Pietras, K., Chou, J., Chen, D., Sennino, B., Hanahan, D., & McDonald, D. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.02.019 · Cited by 56
Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer
Hanna, G. J., Guenette, J. P., Chau, N. G., Sayehli, C. M., Wilhelm, C., Metcalf, R. L., Wong, D. J. L., Brose, M. S., Razaq, M., Pérez-Ruiz, E., et al. (2020) · Cancer · doi:10.1002/cncr.33036 · Cited by 56
Ma, J., & Ge, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.701690 · Cited by 56
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies
Rivas, S., Marín, A., Samtani, S., González, E., & Armisén, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213898 · Cited by 56
PROTACs: Novel tools for improving immunotherapy in cancer
Li, S., Chen, T., Liu, J., Zhang, H., Li, J., Wang, Z. P., & Shang, G. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216128 · Cited by 56
N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation
Groen, R. W. J., de Rooij, M. F. M., Kocemba‐Pilarczyk, K. A., Reijmers, R. M., de Haan-Kramer, A., Overdijk, M. B., Aalders, L., Rozemuller, H., Martens, A. C., Bergsagel, P. L., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.038133 · Cited by 55
Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor HeterogeneityPreprint
Miyamoto, D. T., Ting, D. T., Toner, M., Maheswaran, S., & Haber, D. A. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031120 · Cited by 55
Clinical and prognostic value of the C‐Met/HGF signaling pathway in cervical cancer
Boromand, N., Hasanzadeh, M., Shahidsales, S., Farazestanian, M., Gharib, M., Fiuji, H., Behboodi, N., Ghobadi, N., Hassanian, S. M., Ferns, G. A., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26232 · Cited by 55
High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer
Iwadate, R., Inoue, J., Tsuda, H., Takano, M., Furuya, K., Hirasawa, A., Aoki, D., & Inazawa, J. (2014) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.14048 · Cited by 54
Platelet RNA as Pan-Tumor Biomarker for Cancer Detection
Würdinger, T., Veld, S. G. J. G. I. ‘., & Best, M. G. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3684 · Cited by 54
Calabrese, F., Lunardi, F., Pezzuto, F., Fortarezza, F., Vuljan, S. E., Marquette, C., & Hofman, P. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030414 · Cited by 53
Chu, Y., Yam, C., Yamaguchi, H., & Hung, M. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00870-7 · Cited by 53
Wehler, T., Thomas, M., Schumann, C., Bosch‐Barrera, J., Segarra, N., Dickgreber, N. J., Dalhoff, K., Sebastian, M., Jaime, J. C., Alonso, M. D., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.03.001 · Cited by 52
Scaletti, E. R., Jemth, A., Helleday, T., & Stenmark, P. (2019) · FEBS Letters · doi:10.1002/1873-3468.13455 · Cited by 52
Scanning electron microscopy as a new tool for diagnostic pathology and cell biology
Hyams, T. C., Mam, K., & Killingsworth, M. C. (2019) · Micron · doi:10.1016/j.micron.2019.102797 · Cited by 52
Drug resistance in targeted cancer therapies with RAF inhibitors
Degirmenci, U., Yap, J., Sim, Y. R. M., Qin, S., & Hu, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.36 · Cited by 52
N-Cadherin in Neuroblastoma Disease: Expression and Clinical Significance
Lammens, T., Swerts, K., Derycke, L., Craemer, A. D., Brouwer, S. D., Preter, K. D., Roy, N. V., Vandesompele, J., Speleman, F., Philippé, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031206 · Cited by 51
Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer
Li, Y., Wu, T., Zhang, B., Yao, Y., & Yin, G. (2012) · Medical Oncology · doi:10.1007/s12032-012-0283-z · Cited by 51
Prognostic significance of Bcl-xL gene expression in human colorectal cancer
Yang, J., Wang, Z., Cheng-Yu, L., Liang, X.-D., Ming, S., Yuan-Yuan, G., & De, W. (2011) · Acta Histochemica · doi:10.1016/j.acthis.2011.01.002 · Cited by 51
Usefulness of novel tumour markers
Rhodes, J. M. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s118 · Cited by 51
Lamin‑B1 is a senescence‑associated biomarker in clear‑cell renal cell carcinoma
Radspieler, M., Schindeldecker, M., Stenzel, P., Foersch, S., Tagscherer, K. E., Herpel, E., Hohenfellner, M., Hatiboglu, G., Roth, W., & Macher‐Goeppinger, S. (2019) · Oncology Letters · doi:10.3892/ol.2019.10593 · Cited by 51
Liquid Biopsies in Lung Cancer
Kemper, M., Krekeler, C., Menck, K., Lenz, G., Evers, G., Schulze, A. B., & Bleckmann, A. (2023) · Cancers · doi:10.3390/cancers15051430 · Cited by 51
[25] 125I-labeled protein A: Reactivity with IgG and use as a tracer in radioimmunoassay
Langone, J. J. (1980) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(80)70064-2 · Cited by 50
Farnesyl Thiosalicylic Acid Chemosensitizes Human Melanoma In Vivo
Halaschek-Wiener, J., Kloog, Y., Wacheck, V., & Jansen, B. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12009.x · Cited by 50
Prelude to an Anniversary for the RAS Oncogene
Downward, J. (2006) · Science · doi:10.1126/science.1134727 · Cited by 49
Yun, M., Bai, H.-Y., Zhang, J.-X., Rong, J., Weng, H.-W., Zheng, Z.-S., Xu, Y., Tong, Z., Huang, X.-X., Liao, Y.-J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117375 · Cited by 49
Zhang, H., Ma, Y., Zhang, Y., Cui, J., & Wang, Z. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203926 · Cited by 49
Self-citationMa, B., Wells, A. H., & Clark, A. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.021 · Cited by 49
Cellular senescence and hematological malignancies: From pathogenesis to therapeutics
Hu, D., Yuan, S., Zhong, J., Liu, Z., Wang, Y., Liu, L., Li, J., Wen, F., Liu, J., & Zhang, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107817 · Cited by 49
Targeting necroptosis as an alternative strategy in tumor treatment: From drugs to nanoparticles
Zang, X., Song, J., Li, Y., & Han, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.060 · Cited by 49
Halaschek-Wiener, J., Wacheck, V., Schlagbauer‐Wadl, H., Wolff, K. S., Kloog, Y., & Jansen, B. (2000) · Molecular Medicine · doi:10.1007/bf03402049 · Cited by 48
Manoochehri, M., Karbasi, A., Bandehpour, M., & Kazemi, B. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-013-9695-0 · Cited by 48
Zhang, P., Xu, B., Gui, L., Wang, W., Xiu, M., Zhang, X., Sun, G., Zhu, X., & Zou, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00271-2 · Cited by 48
Autophagy-targeted nanoparticles for effective cancer treatment: advances and outlook
Long, X., Yan, J., Zhang, Z., Chang, J., He, B., Sun, Y. Y., & Liang, Y. (2022) · NPG Asia Materials · doi:10.1038/s41427-022-00422-3 · Cited by 48
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy
Rizk, E. M., Gartrell, R. D., Barker, L. W., Esancy, C. L., Finkel, G. G., Bordbar, D. D., & Saenger, Y. M. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.005 · Cited by 47
ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias
Boudný, M., & Trbušek, M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102026 · Cited by 47
Lee, H. W., Sa, J. K., Gualberto, A., Scholz, C. R., Sung, H. H., Jeong, B. C., Choi, H. Y., Kwon, G. Y., & Park, S. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1246 · Cited by 47
Su, M., Gong, X.-Y., & Liu, F. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1877656 · Cited by 47
Ye, X., Gaucher, J., Vidal, M., & Broussy, S. (2021) · Molecules · doi:10.3390/molecules26226759 · Cited by 47
Pasupuleti, N., Leon, L. J., Carraway, K. L., & Gorin, F. A. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.200519 · Cited by 46
Yuan, G., Niu, L., Zhang, Y., Wang, X., Ma, K., Yin, H., Dai, J., Zhou, W., & Pan, Y. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2433-9 · Cited by 46
Self-citationLi, H., Deng, N.-H., Xiu-sheng, H., & Li, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00397-x · Cited by 46
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
Kristeleit, R. S., Plummer, R., Jones, R., Carter, L., Blagden, S. P., Sarker, D., Arkenau, H., Evans, T. R. J., Danson, S. J., Symeonides, S. N., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02279-x · Cited by 46
Liu, Y., Wu, K., Shi, L., Xiang, F., Tao, K., & Wang, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166230 · Cited by 45
Targeting the HGF/c-Met Axis: State of Play
Yap, T. A., & Bono, J. S. D. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0122 · Cited by 44
Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Bouchalová, K., Kharaishvili, G., Bouchal, J., Vrbková, J., Houdova, M. M., & Hlobílková, A. (2014) · Current Drug Targets · doi:10.2174/1389450115666141106151143 · Cited by 44
Tarhini, A. A., Rafique, I., Floros, T., Tran, P. N., Gooding, W. E., Villaruz, L., Burns, T. F., Friedland, D., Petro, D. P., Farooqui, M., et al. (2017) · Cancer · doi:10.1002/cncr.30717 · Cited by 44
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
Palumbo, A., Lau, G., & Saraceni, M. M. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018795146 · Cited by 44
Cheng, H., He, W., Yang, J., Ye, Q., Cheng, L. Y., Pan, Y., Mao, L., Chu, X., Lu, C., Li, G., et al. (2020) · Cell Proliferation · doi:10.1111/cpr.12880 · Cited by 44
Targeting allosteric regulation of cancer metabolism
Kremer, D. M., & Lyssiotis, C. A. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00997-6 · Cited by 44
Zhang, Y., Sun, M., Huang, G., Yin, L., Lai, Q., Yang, Y., Xing, X., Yu, G., Sun, Y., Wang, X., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705066114 · Cited by 43
Self-citationBRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers
Wang, G., Zhao, C., Huang, Y., Wang, W., Zhang, S., & Wang, X. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.10.032 · Cited by 43
Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach
Ricciardi, E., Giordani, E., Ziccheddu, G., Falcone, I., Giacomini, P., Fanciulli, M., Russillo, M., Cerro, M., Ciliberto, G., Morrone, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044014 · Cited by 43
Fibroblast growth factor receptors in breast cancer
Wang, S., & Ding, Z. (2017) · Tumor Biology · doi:10.1177/1010428317698370 · Cited by 42
Combination of ULK1 and LC3B improve prognosis assessment of hepatocellular carcinoma
Wu, D., Wang, T.-T., Ruan, D., Li, X., Chen, Z., Wen, J., Lin, Q., Ma, X., Wu, X., & Jia, C. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.025 · Cited by 42
Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials
Toson, B., Fortes, I. S., Roesler, R., & de Andrade, S. F. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106403 · Cited by 42
Hultberg, A., Morello, V., Huyghe, L., Jonge, N. D., Blanchetot, C., Hanssens, V., Boeck, G. D., Silence, K., Festjens, E., Heukers, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0356 · Cited by 41
Hypoxia-Induced Lactate Dehydrogenase Expression and Tumor Angiogenesis
Colgan, S. M., Mukherjee, S. D., & Major, P. P. (2007) · Clinical Colorectal Cancer · doi:10.3816/ccc.2007.n.014 · Cited by 41
EMT promoting transcription factors as prognostic markers in human breast cancer
Matysiak‐Kucharek, M., Kapka‐Skrzypczak, L., Jodłowska‐Jędrych, B., & Kruszewski, M. K. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4304-1 · Cited by 41
Bernat‐Peguera, A., Simón-Extremera, P., da Silva-Diz, V., de Munain, M. L., Díaz-Gil, L., Penin, R. M., González‐Suárez, E., Sidelnikova, D. P., Bermejo, O., Viñals, J. M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0773-y · Cited by 41
BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma
Jin, T. Y., Park, K. S., Nam, S. E., Yoo, Y. B., Park, W. S., & Yun, I. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073754 · Cited by 41
Coppin, C. (2010) · Biologics · doi:10.2147/btt.s6748 · Cited by 40
The Akt/mTOR and Mitogen-Activated Protein Kinase Pathways in Lung Cancer Therapy
Papadimitrakopoulou, V. A., & Adjei, A. A. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30399-3 · Cited by 40
Sun, Y., Jing, J., Xu, H., Xu, L., Hu, H., Tang, C., Liu, S., Wei, Q., Duan, R., Guo, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002138 · Cited by 40
Immunohistochemical Analysis of E-Cadherin Expression in Human Colorectal Tumours
Aken, J. V., Cuvelier, C. A., Wever, N. D., Roels, J., Gao, Y., & Mareel, M. (1993) · Pathology - Research and Practice · doi:10.1016/s0344-0338(11)80667-9 · Cited by 39
Rosemblit, C., Datta, J., Lowenfeld, L., Xu, S., Basu, A. B., Kodumudi, K. N., Wiener, D. A., & Czerniecki, B. J. (2018) · Oncotarget · doi:10.18632/oncotarget.25208 · Cited by 39
Role of HGF/c‐Met in the treatment of colorectal cancer with liver metastasis
Yao, J., Li, X., Yan, L., He, S., Zheng, J., Wang, X., Zhou, P., Zhang, L., Wei, G., & Sun, X. (2019) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22316 · Cited by 39
Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting
Yaeger, R., & Solit, D. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4060 · Cited by 39
Measurement of Serum Neuron-Specific Enolase in Neuroblastoma: Is There a Clinical Role?
Ferraro, S., Braga, F., Luksch, R., Terenziani, M., Caruso, S., & Panteghini, M. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa073 · Cited by 39
Arulananda, S., O’Brien, M., Evangelista, M., Jenkins, L. J., Poh, A. R., Walkiewicz, M., Leong, T. Y.-M., Mariadason, J. M., Cebon, J. S., Balachander, S. B., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00505-0 · Cited by 39
Understanding Necroptosis in Pancreatic Diseases
He, R., Wang, Z., Dong, S., Chen, Z., & Zhou, W. (2022) · Biomolecules · doi:10.3390/biom12060828 · Cited by 39
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症:英文版 · doi:10.1002/cac2.12377 · Cited by 39
The inhibition of invasion of human melanoma cells through N-cadherin knock-down
Ciołczyk-Wierzbicka, D., & Laidler, P. M. (2018) · Medical Oncology · doi:10.1007/s12032-018-1104-9 · Cited by 38
Tuttle, R., Miller, K. R., Maiorano, J. N., Termuhlen, P. M., Gao, Y., & Berberich, S. J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26239 · Cited by 37
TERT Extra-Telomeric Roles: Antioxidant Activity and Mitochondrial Protection
Marinaccio, J., Micheli, E., Udroiu, I., Nottia, M. D., Carrozzo, R., Baranzini, N., Grimaldi, A., Leone, S., Moreno, S., Muzzi, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054450 · Cited by 37
CRISPR-Cas9 Targeted Enrichment and Next-Generation Sequencing for Mutation Detection
Malekshoar, M., Azimi, S. A., Kaki, A., Mousazadeh, L., Motaei, J., & Vatankhah, M. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.01.010 · Cited by 37
Zhao, J., Yu, X., Shentu, X., & Li, D. (2024) · Cell and Tissue Research · doi:10.1007/s00441-024-03878-7 · Cited by 37
Identification of a consensus site for TRAF6/p62 polyubiquitination
Jadhav, T., Geetha, T., Jiang, J., & Wooten, M. W. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.138 · Cited by 36
The sensitivity and specificity of serum glycan-based biomarkers for cancer detection
Tang, Y., Cui, Y., Zhang, S., & Zhang, L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.01.010 · Cited by 36
A Sos proteomimetic as a pan-Ras inhibitor
Hong, S. H., Yoo, D. Y., Conway, L. P., Richards-Corke, K. C., Parker, C. G., & Arora, P. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101027118 · Cited by 36
Shi, C., Liu, S., Tian, X., Wang, X., & Gao, P. (2021) · BMC Cancer · doi:10.1186/s12885-021-08765-w · Cited by 36
Self-citationThe Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis
Chang, C., Shih, A. C.-C., Chang, Y.-H., Chen, H., Chao, Y., & Hsu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759497 · Cited by 36
Yue, K., Qin, M., Huang, C., Chou, C. J., Jiang, Y., & Li, X. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128797 · Cited by 36
Role of inflammasomes and their regulators in prostate cancer initiation, progression and metastasis
Veeranki, S. (2013) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-013-0095-y · Cited by 35
The role of necroptosis, an alternative form of cell death, in cancer therapy
Yu, X., Deng, Q., Bode, A. M., Dong, Z., & Cao, Y. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.811180 · Cited by 35
Correlation of Altered Expression of the Autophagy Marker LC3B with Poor Prognosis in Astrocytoma
Winardi, D., Tsai, H., Chai, C., Chung, C., Loh, J., Chen, Y., & Hsieh, C. (2014) · BioMed Research International · doi:10.1155/2014/723176 · Cited by 35
High molecular weight epithelial mucins as markers in breast cancer
Price, M. R. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90088-0 · Cited by 35
High expression levels of unc-51-like kinase 1 as a predictor of poor prognosis in colorectal cancer
Zou, Y., Chen, Z., He, X., He, X., Wu, X., Chen, Y., Wu, X., Wang, J., & Lan, P. (2015) · Oncology Letters · doi:10.3892/ol.2015.3417 · Cited by 35
Circulating Cell Free DNA in the Diagnosis of Trophoblastic Tumors
Openshaw, M. R., Harvey, R. A., Sebire, N. J., Kaur, B. S., Sarwar, N., Seckl, M. J., & Fisher, R. A. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.12.022 · Cited by 35
Xiong, H., Nie, X., 邹燕梅, Gong, C., Li, Y., Qiu, H., Qiu, H., Yang, L., Zhuang, L., Zhang, J., et al. (2017) · Journal of Cancer · doi:10.7150/jca.16607 · Cited by 35
Lowery, C. D., Blosser, W. D., Dowless, M. S., Knoche, S. M., Stephens, J. R., Li, H., Surguladze, D., Loizos, N., Luffer, D. R., Oakley, G. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1258 · Cited by 35
Regulation of Autophagic Flux by the 20S Proteasome
Njomen, E., & Tepe, J. J. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.07.002 · Cited by 35
Therapeutic targeting of N‐cadherin is an effective treatment for multiple myeloma
Mrozik, K. M., Cheong, C. M., Hewett, D. R., Chow, A. W. S., Blaschuk, O. W., Zannettino, A. C. W., & Vandyke, K. (2015) · British Journal of Haematology · doi:10.1111/bjh.13596 · Cited by 34
Lee, B.-S., Kang, S. Y., Kim, K.-A., Song, Y.-J., Cheong, K. H., Cha, H.-Y., & Kim, C. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.119 · Cited by 34
Hu, Y., Bobb, D., He, J., Hill, D. A., & Dome, J. S. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1040964 · Cited by 33
Monitoring and Measuring Mammalian Autophagy
Bhutia, S. K., Praharaj, P. P., Bhol, C. S., Panigrahi, D. P., Mahapatra, K. K., Patra, S., Saha, S., Das, D. N., Mukhopadhyay, S., Sinha, N., et al. (2018) · Methods in molecular biology · doi:10.1007/7651_2018_159 · Cited by 33
Cho, J., Kim, K., Kim, H. C., Lee, W. Y., Kang, W. K., Park, Y. S., & Ha, S. Y. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.10.024 · Cited by 33
Quantitative microimmunohistochemistry for the grading of immunostains on tumour tissues
Kashyap, A., Khartchenko, A. F., Pati, P., Gabrani, M., Schraml, P., & Kaigala, G. V. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0386-3 · Cited by 33
ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Tew, B. Y., Kalfa, A. J., Yang, Z., Hurth, K. M., Simon, T., Abnoosian, E., Durant, S. T., Hamerlik, P., & Salhia, B. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0290 · Cited by 33
Retinoblastoma gene in mouse neural development
Slack, R. S., & Miller, F. D. (1996) · Developmental Genetics · doi:10.1002/(sici)1520-6408(1996)18:1<81::aid-dvg9>3.0.co;2-y · Cited by 32
Buchanan, F. G., Chang, W., Sheng, H., Shao, J., Morrow, J. D., & DuBois, R. N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.025 · Cited by 32
Zec, M. M., Srdić‐Rajić, T., Krivokuća, A., Jankovic, R. N., Todorović, T. R., Anđelković, K., & Radulovic, S. S. (2014) · Medicinal Chemistry · doi:10.2174/1573406410666140327122009 · Cited by 32
Duarte, V. D. S., Cruz, B. C. D. S., Tarrah, A., Dias, R. S., Moreira, L. D. P. D., Lemos, W. J. F., Silva, L. C. F., Santana, G. R., de Oliveira, L. L., Pelúzio, M. D. C. G., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8121994 · Cited by 32
Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
Brahmi, M., Lesluyes, T., Dufresne, A., Toulmonde, M., Italiano, A., Mir, O., Cesne, A. L., Valentin, T., Chevreau, C., Bonvalot, S., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100037 · Cited by 32
Hack, C. E., Paardekooper, J., Eerenberg, A. J. M., Navis, G. O., Nijsten, M. W., Thijs, L. G., & Nuijens, J. H. (1988) · Journal of Immunological Methods · doi:10.1016/0022-1759(88)90405-x · Cited by 31
Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells
Yue, W., Wang, J., Li, Y., Fan, P., & Santen, R. J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21222 · Cited by 31
Kim, R. Y., Xu, H., Myllykangas, S., & Ji, H. P. (2011) · Personalized Medicine · doi:10.2217/pme.11.16 · Cited by 31
Guo, G., Wang, Y., Zhang, Y., Chen, X., Lu, J., Wang, H., Jiang, C., Qiu, H.-Q., & Xia, L. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i15.1840 · Cited by 31
Self-citationLiu, D., Luo, Y., Chen, L., Chen, L.-W., Zuo, D., Li, Y., Zhang, X., Wu, J., Xi, Q., Li, G., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0207 · Cited by 31
Extracellular Vesicle-DNA: The Next Liquid Biopsy Biomarker for Early Cancer Diagnosis?
Tatischeff, I. (2023) · Cancers · doi:10.3390/cancers15051456 · Cited by 31
Deryugina, E. I., Ratnikov, B. I., & Strongin, A. Y. (2003) · International Journal of Cancer · doi:10.1002/ijc.10977 · Cited by 30
Outline of gelatinase inhibitors as anti-cancer agents: A patent mini-review for 2010-present
Baidya, S. K., Amin, S. A., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113044 · Cited by 30
Twist as a new prognostic marker in hematological malignancies
Norozi, F., Ahmadzadeh, A., Shahjahani, M., Shahrabi, S., & Saki, N. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1357-0 · Cited by 29
LC3B globular structures correlate with survival in esophageal adenocarcinoma
El-Mashed, S., O’Donovan, T. R., Kay, E. W., Abdallah, A. R., Cathcart, M., O'Sullivan, J. N., O’Grady, A., Reynolds, J. V., O’Reilly, S., O’Sullivan, G. C., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1574-5 · Cited by 29
Hantusch, A., Das, K. K., García‐Sáez, A. J., Brunner, T., & Rehm, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0464-6 · Cited by 29
Review of Immunohistochemistry Biomarkers in Pancreatic Cancer Diagnosis
Tuấn, L. T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.799025 · Cited by 29
Frontline therapy for advanced hepatocellular carcinoma: an update
Akce, M., El‐Rayes, B. F., & Bekaii‐Saab, T. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221086126 · Cited by 29
Hosseini, S. A., Jouneghani, A. S., Ghatrehsamani, M., Yaghoobi, H., Elahian, F., & Mirzaei, S. A. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.018 · Cited by 29
Telomerase-targeted therapies in myeloid malignancies
Waksal, J. A., Bruedigam, C., Komrokji, R. S., Jamieson, C. H. M., & Mascarenhas, J. O. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009903 · Cited by 29
Waters, N. J., Daigle, S. R., Rehlaender, B. N., Basavapathruni, A., Campbell, C. T., Jensen, T. B., Truitt, B. F., Olhava, E. J., Pollock, R. M., Stickland, K., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.023 · Cited by 28
Tartaglione, S., Granato, T., Anastasi, E., Angeloni, A., Marchese, C., Manganaro, L., Viggiani, V., Zarrillo, S. R., & Pecorella, I. (2019) · Biochemia Medica · doi:10.11613/bm.2019.020707 · Cited by 28
Genomics and prognosis analysis of epithelial-mesenchymal transition in colorectal cancer patients
Zhang, Z., Zheng, S., Lin, Y., Sun, J., Ding, N., Chen, J., Zhong, J., Shi, L., & Xue, M. (2020) · BMC Cancer · doi:10.1186/s12885-020-07615-5 · Cited by 28
Girardi, D. M., Niglio, S. A., Mortazavi, A., Nadal, R., Lara, P. N., Pal, S. K., Saraiya, B., Cordes, L., Ley, L., Ortiz, O. S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3726 · Cited by 28
Lamin B1 is a potential therapeutic target and prognostic biomarker for hepatocellular carcinoma
Yang, Y., Gao, L., Chen, J., Wang, X., Liu, R., & Kan, H. (2022) · Bioengineered · doi:10.1080/21655979.2022.2057896 · Cited by 28
KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer
Dai, M., Chen, S., Teng, X., Chen, K., & Cheng, W. (2022) · Journal of Cancer · doi:10.7150/jca.76695 · Cited by 28
Senapati, J., Müftüoğlu, M., Ishizawa, J., Abbas, H. A., Loghavi, S., Borthakur, G. M., Yilmaz, M. E., Issa, G. C., Dara, S., Basyal, M., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00871-1 · Cited by 28
In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Jehan, Z., Shahab Uddin, M. S., & Al-Kuraya, K. S. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712801661031 · Cited by 27
Zeb1 in Stromal Myofibroblasts Promotes Kras -Driven Development of Pancreatic Cancer
Sangrador, I., Molero, X., Campbell, F., Franch‐Expósito, S., Rovira-Rigau, M., Samper, E., Domínguez-Fraile, M., Fillat, C., Castells, A., & Vaquero, E. C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1882 · Cited by 27
Ban, L.-X., Mei, T., Su, Q., Li, W., Huang, Z., Liu, L., Wu, Y., Lv, S., Wang, A., & Su, L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117695 · Cited by 27
Sun, L., Wang, R.-C., Zhang, Q., & Guo, L. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153032 · Cited by 27
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)
Smolarz, B., Łukasiewicz, H., Samulak, D., Piekarska, E., Kołaciński, R., & Romanowicz, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052049 · Cited by 259
Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Alum, E., Izah, S., Uti, D., Ugwu, O., Betiang, P., Basajja, M., & Ejemot-Nwadiaro, R. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s543211 · Cited by 63
Metadata
- Authors
- Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-05-20
- Volume
- 9
- Issue
- 1
- Pages
- 132-132
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4397293886
- Cited by
- 720
- References
- 1,264
- FWCI
- 109.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.